HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mary Jo Laffler

Mary Jo Laffler oversees US commercial content for Informa’s pharmaceutical news publications, working with a group of talented reporters and editors covering business, commercial and clinical news. She brings 16 years of experience reporting on the pharmaceutical industry for the Pink Sheet and affiliated publications, serving previously as Bureau Chief for Clinical Development and Business News, managing editor of the Pink Sheet and as one of the first managing editors for the Pink Sheet DAILY. While wearing many hats has given Mary Jo a wide-ranging knowledge of the commercial and regulatory challenges facing the pharmaceutical industry, her specialty is in analyzing drug development news and R&D strategy.

Latest From Mary Jo Laffler

How Biogen’s Aduhelm Bet Became A Commercial Bust

Biogen caught a lucky break in getting the first FDA approval for a potentially disease-modifying Alzheimer’s therapy, but doubt over clinical benefit and commercial missteps have left Biogen in a precarious position a year later. 

Launches Market Access

How Biogen’s Aduhelm Bet Became A Commercial Bust

Biogen caught a lucky break in getting the first FDA approval for a potentially disease-modifying Alzheimer’s therapy, but doubt over clinical benefit and commercial missteps have left Biogen in a precarious position a year later. 

Launches Market Access

Publisher’s Spotlight: Citeline Awards Honor R&D Excellence

Pharma Intelligence congratulates the winners of the 2021 Citeline Awards. 

Clinical Trials Diversity & Inclusion

Publisher’s Spotlight: Citeline Awards Honor R&D Excellence

Pharma Intelligence congratulates the winners of the 2021 Citeline Awards. 

Clinical Trials Diversity & Inclusion

US FDA Authorizes Pfizer's Paxlovid, In The Nick Of Time

The US FDA’s Christmas gift was the authorization of the first oral pill for treatment of mild-to-moderate COVID-19; Pfizer expects to have 30 million doses of Paxlovid available by mid-2022.

Coronavirus COVID-19 Launches

Takeda's Livtencity Approved For Refractory CMV Infection In Transplant Patients

Maribavir is the first antiviral agent targeting and inhibiting the pUL97 protein kinase, as well as Takeda's second new molecular entity approved by FDA this year.

Approvals Business Strategies
See All
UsernamePublicRestriction

Register